PR Newswire
17 May 2023, 06:00 GMT+10
![]() |
SHANGHAI and HONG KONG, May 17, 2023 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced that it has submitted New Drug Applications (NDAs) for XPOVIO (selinexor) to the Indonesia National Agency of Drug and Food Control (BPOM) for the treatment of relapsed/refractory multiple myeloma (R/R MM) and relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). In Q4 2022, Antengene also submitted NDAs for XPOVIO in Malaysia and Thailand.
"In just six months, we have submitted NDAs for XPOVIO in three ASEAN countries, Malaysia, Thailand and Indonesia, supporting our plans to expand commercial presence in the APAC region," said Thomas Karalis, Antengene's Corporate Vice President, Head of Asia Pacific Region. "In a region characterized by countries with large populations and in many cases a lack of access to novel therapeutics, patients with R/R MM or DLBCL have urgent unmet needs for innovative, effective treatments. We hope XPOVIO can address this unmet need and bring a new treatment option to patients with R/R MM and R/R DLBCL in these underserved markets."
"Established in China with a growing presence in the APAC region and a clear roadmap for global expansion, Antengene is striving to build up strong commercial capabilities in the ASEAN countries that has a total population exceeding 600 million and establish a global commercial infrastructure that will allow us to bring more breakthrough therapies to patients around the world," said Dr. Jay Mei, Antengene's Founder, Chairman and CEO. "In the past six months, we submitted NDAs for XPOVIO in three key ASEAN countries. This achievement is a testament to the effective execution by our teams and the company's commitment to bringing more innovative drugs to patients around the world. Moving forward, we will continue to excel in execution and maintain close contacts with the regulatory authorities of these countries for the approval of XPOVIO."
About XPOVIO (selinexor)
XPOVIO is the world's first approved orally-available, selective inhibitor of the nuclear export protein XPO1. It offers a novel mechanism of action, synergistic effects in combination regimens, fast onset of action, and durable responses.
By blocking the nuclear export protein XPO1, XPOVIO can promote the intranuclear accumulation and activation of tumor suppressor proteins and growth regulating proteins, and down-regulate the levels of multiple oncogenic proteins. XPOVIO delivers its antitumor effects through three mechanistic pathways: 1) exerting antitumor effects by inducing the intranuclear accumulation of tumor suppressor proteins; 2) reducing the level of oncogenic proteins in the cytoplasm by inducing the intranuclear accumulation of oncogenic mRNAs; 3) restoring hormone sensitivity by activating the glucocorticoid receptors (GR) pathway. To utilize its unique mechanism of actions, XPOVIO is being evaluated for use in multiple combination regimens in a range of indications. At present, Antengene is conducting 8 clinical studies of XPOVIO in mainland China for the treatment of relapsed/refractory hematologic malignancies and solid tumors (3 global clinical studies of these are being jointly conducted by Antengene and Karyopharm Therapeutics Inc. [Nasdaq:KPTI]).
XPOVIO is approved in South Korea for the following two indications:
XPOVIO is approved in mainland China for the following indication:
XPOVIO is approved in Taiwan, China for the treatment of the following three indications:
XPOVIO is approved in Australia for the following two indications:
XPOVIO is approved in Singapore for the following three indications:
About Antengene
Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) is a leading commercial-stage R&D-driven global biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative first-in-class/best-in-class therapeutics for the treatment of hematologic malignancies and solid tumors, in realizing its vision of "Treating Patients Beyond Borders".
Since 2017, Antengene has built a pipeline of 9 oncology assets at various stages going from clinical to commercial, including 6 with global rights, and 3 with rights for the APAC region. To date, Antengene has obtained 28 investigational new drug (IND) approvals in the U.S. and Asia, and submitted 10 new drug applications (NDAs) in multiple Asia Pacific markets, with the NDA for XPOVIO (selinexor) already approved in Mainland of China, Taiwan China, South Korea, Singapore and Australia.
Forward-looking statements
The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, see the other risks and uncertainties described in the Company's Annual Report for year-end December 31, 2022, and subsequent filings with the Hong Kong Stock Exchange.
For more information, please contact:
Investor Contacts:
Donald Lung
E-mail: [email protected]
Mobile: +86 18420672158
PR Contacts:
Peter Qian
E-mail: [email protected]
Mobile: +86 13062747000
Get a daily dose of Malaysia Sun news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Malaysia Sun.
More InformationBANGKOK, Thailand: Thailand's finance ministry has revised its projection for foreign tourist arrivals this year, lowering the estimate...
Raipur (Chhattisgarh) [India], May 8 (ANI): As India strikes against Pakistan in retaliation against the Pahalgam terror attack under...
Jaipur (Rajasthan) [India], May 8 (ANI): Rajasthan Leader of Opposition (LoP) and Congress MLA Tika Ram Jully expressed pride in the...
New Delhi [India], May 8 (ANI): Global economic growth is expected to decelerate in the coming months, with major economies like the...
Dhaka [Bangladesh], May 8 (ANI): Bangladesh's former President Abdul Hamid left the country nine months after the Awami League government...
DUBAI, 8th May, 2025 (WAM) -- Dubai International Chamber, one of the three chambers operating under the umbrella of Dubai Chambers,...
IRVING, Texas: Kimberly-Clark, the maker of Kleenex tissues and Huggies diapers, announced this week it will invest US$2 billion over...
HONG KONG: Hong Kong's economy grew by 3.1 percent in the first quarter of this year compared to the same period last year, according...
NEW YORK, New York - U.S. stocks advanced on Wednesday while the U.S. dollar made across-the-board gains after the Federal Reserve...
LONG ISLAND CITY, New York: JetBlue Airways' plan to strike a domestic partnership with another U.S. airline is drawing sharp resistance...
LONDON, U.K.: Shell reported a better-than-expected first-quarter profit of US$5.58 billion on May 2, down 28 percent from a year earlier...
BANGKOK, Thailand: Thailand's finance ministry has revised its projection for foreign tourist arrivals this year, lowering the estimate...